MetaADEDB 2.0 @ LMMD
Hemin
(BTIJJDXEELBZFS-UHFFFAOYSA-K)
Structure
SMILES
C=CC1=C(C)C2=NC1=Cc1[n-]c(c(c1C)CCC(=O)O)C=c1[n-]c(=CC3=NC(=C2)C(=C3C)C=C)c(c1CCC(=O)O)C.[Cl-].[Fe+3]
Molecular Formula:
C34H32ClFeN4O4
Molecular Weight:
651.940
Log P:
-0.1132
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
2
TPSA:
125.1
CAS Number(s):
16009-13-5
Synonym(s)
1.
Hemin
2.
Ferriprotoporphyrin
3.
Hematin
4.
Alkaline Hematin D-575
5.
Chlorohemin
6.
Ferrihaem
7.
Ferriheme Chloride
8.
Ferriprotoporphyrin IX
9.
Ferriprotoporphyrin IX Chloride
10.
Panhematin
11.
Protohemin
12.
Protohemin IX
13.
Alkaline Hematin D 575
14.
Chloride, Ferriheme
15.
Chloride, Ferriprotoporphyrin IX
16.
Hematin D-575, Alkaline
External Link(s)
MeSHD006427
PubChem Compound52993227
455658
53627695
5318002
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Device occlusionFAERS: 13US FAERS
2PhlebitisFAERS: 7US FAERS
3ExtravasationFAERS: 5US FAERS
4NauseaFAERS: 5US FAERS
5Infusion Site ExtravasationFAERS: 4US FAERS
6MalaiseFAERS: 4US FAERS
7Chest PainFAERS: 3US FAERS
8FatigueFAERS: 3US FAERS
9Infusion site painFAERS: 3US FAERS
10Iron OverloadFAERS: 3US FAERS
11No adverse eventFAERS: 3US FAERS
12PainFAERS: 3US FAERS
13ThrombocytopeniaFAERS: 3US FAERS
14VomitingFAERS: 3US FAERS
15Accidental exposure to productFAERS: 2US FAERS
16Adverse eventFAERS: 2US FAERS
17Chest discomfortFAERS: 2US FAERS
18Deep Vein ThrombosisFAERS: 2US FAERS
19HeadacheFAERS: 2
Canada Vigilance: 1		Canada Vigilance
US FAERS
20HypersensitivityFAERS: 2US FAERS
21Infusion site erythemaFAERS: 2US FAERS
22Infusion site indurationFAERS: 2US FAERS
23Injection site painFAERS: 2US FAERS
24Abdominal PainFAERS: 1US FAERS
25Administration site necrosisFAERS: 1US FAERS
26AgitationFAERS: 1US FAERS
27Back PainFAERS: 1US FAERS
28Blood blisterFAERS: 1US FAERS
29Blood erythropoietin increasedFAERS: 1US FAERS
30Catheter site extravasationFAERS: 1US FAERS
31ChillsFAERS: 1US FAERS
32Critical IllnessFAERS: 1US FAERS
33Drug ineffectiveFAERS: 1US FAERS
34EmbolismFAERS: 1US FAERS
35ErythemaFAERS: 1US FAERS
36Feeling abnormalFAERS: 1US FAERS
37FlushingFAERS: 1US FAERS
38General physical health deteriorationFAERS: 1US FAERS
39Hyperviscosity syndromeFAERS: 1US FAERS
40HypotensionFAERS: 1US FAERS
41Inappropriate schedule of drug administrationFAERS: 1US FAERS
42Incorrect dose administeredFAERS: 1US FAERS
43Incorrect route of drug administrationFAERS: 1US FAERS
44Incorrect route of product administrationFAERS: 1US FAERS
45Infusion site bruisingFAERS: 1US FAERS
46Infusion site massFAERS: 1US FAERS
47Infusion site swellingFAERS: 1US FAERS
48Infusion site vesiclesFAERS: 1US FAERS
49Infusion site warmthFAERS: 1US FAERS
50Injection Site ReactionFAERS: 1US FAERS
51Injection site extravasationFAERS: 1US FAERS
52Injection site phlebitisFAERS: 1US FAERS
53Medical device complicationFAERS: 1US FAERS
54Mental impairmentFAERS: 1US FAERS
55Mental status changesFAERS: 1US FAERS
56Musculoskeletal stiffnessFAERS: 1US FAERS
57NasopharyngitisFAERS: 1US FAERS
58Oropharyngeal painFAERS: 1US FAERS
59PancytopeniaFAERS: 1US FAERS
60Patient dissatisfaction with treatmentFAERS: 1US FAERS
61Peripheral swellingFAERS: 1US FAERS
62Platelet function test abnormalFAERS: 1US FAERS
63PneumoniaFAERS: 1US FAERS
64Product dose omissionFAERS: 1US FAERS
65Product label confusionFAERS: 1US FAERS
66Product packaging quantity issueFAERS: 1US FAERS
67Product preparation issueFAERS: 1US FAERS
68Product reconstitution quality issueFAERS: 1US FAERS
69Product supply issueFAERS: 1US FAERS
70Product use issueFAERS: 1US FAERS
71SinusitisFAERS: 1US FAERS
72TachycardiaFAERS: 1US FAERS
73Unevaluable eventFAERS: 1US FAERS
74UrticariaFAERS: 1US FAERS
75Vascular access site complicationFAERS: 1US FAERS
76Vasculitic rashFAERS: 1US FAERS
77Wrong technique in drug usage processFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120262

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.